SCHEMBL13767265

SCHEMBL13767265

CC(=O)N1CCC(CCn2ncc(C(=O)NC3C4CC5CC(C4)CC3C5)c2OCC(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 12/20 0.41
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
CNR2 P34972 2/20 0.37
IDH1 O75874 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13767259 0.91 KDM4E (0.41) HSD11B1LMNAHTTHPGD
SCHEMBL13767263 0.90 HSD11B1 (0.39) HSD11B1LMNAHTTCNR2IDH1
SCHEMBL13767301 0.89 HSD11B1 (0.41) HSD11B1LMNAHTTCNR2IDH1
SCHEMBL13767303 0.88 HSD11B1 (0.42) HSD11B1LMNAHTTCNR2HPGD
SCHEMBL13767096 0.85 HSD11B1 (0.53) HSD11B1IDH1
SCHEMBL13767288 0.85 HSD11B1 (0.38) HSD11B1LMNAHTTCNR2IDH1
SCHEMBL13766835 0.83 HSD11B1 (0.48) HSD11B1LMNAHTTCNR2HPGD
SCHEMBL13766904 0.82 HSD11B1 (0.47) HSD11B1LMNAHTTHPGDSMN1; SMN2
SCHEMBL13767286 0.82 HSD11B1 (0.39) HSD11B1LMNAHTTCNR2
SCHEMBL13767087 0.82 HSD11B1 (0.47) HSD11B1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1953145-B1 HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE I SHIONOGI & CO (JP) 2015-11-04 EP disclosed
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed
EP-1953145-A1 HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11- -HYDROXYSTEROID DEHYDROGENASE TYPE I Shionogi & Co., Ltd. (JP) 2008-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY HSD17B1, HSD11B1, HSD3B1 HSD11B1 2/4885LMNA 2271/4885HTT 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.